Published on November 1, the USPSTF reaffirmed their stance against use of hormone therapy for primary prevention of chronic conditions in postmenopausal persons, which was the stance the organization took in their 2017 recommendations.
New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.
Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.
An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Data from Sweden national registers provide insight into the increased risk of adverse outcomes, including fracture, cardiovascular events, and mortality risk, associated with primary hyperparathyroidism as well as the apparent reductions in risk achieved by undergoing parathyroidectomy.
On March 29, Antares Pharma announced the FDA granted approval to their oral testosterone replacement therapy option, testosterone udecanoate (TLANDO), for conditions associated with a deficiency or absence of endogenous testosterone or hypogonadism in adult males.